Literature DB >> 2478799

Calcium-sensitivity modulation of cardiac myofibrillar proteins.

J C Rüegg1, I Morano.   

Abstract

Myocardial contractile force may be altered not only by changing intracellular free Ca2+ but also by increasing or decreasing the calcium responsiveness of the myofilaments. The latter effect may be due to interventions that decrease the calcium affinity of troponin C, such as intracellular acidosis or factors that act "downstream" of the calcium-troponin-C interaction in the process of muscle activation. These include inorganic phosphate, which accumulates under hypoxic conditions. Conversely, calcium responsiveness may be increased by drugs that probably increase the calcium affinity of troponin C, such as sulmazole, adibendan, pimobendan, and isomazole. These and related drugs also increase the force development of skinned trabeculae that are submaximally activated by Ca2+ stimulation in ATP salt solution. Thus, we confirmed earlier studies showing that adibendan increased submaximal Ca2+-activated force of pig-heart trabecula skinned by 0.5% lubrol-WX. Qualitatively similar results were obtained with pimobendan. However, calcium responsiveness may not only be modulated by factors influencing troponin, but also by modulation of crossbridge rate constants as well as by other factors that act downstream of troponin C. These include peptides derived from thin-filament proteins and subfragment S1 of myosin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478799     DOI: 10.1097/00005344-198914003-00005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

Review 1.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

2.  The effect of calcium in the production of muscular work.

Authors:  E W Becker
Journal:  Naturwissenschaften       Date:  1990-10

3.  Recombinant troponin I substitution and calcium responsiveness in skinned cardiac muscle.

Authors:  J D Strauss; J E Van Eyk; Z Barth; L Kluwe; R J Wiesner; K Maéda; J C Rüegg
Journal:  Pflugers Arch       Date:  1996-04       Impact factor: 3.657

4.  A new in vitro motility assay technique to evaluate calcium sensitivity of the cardiac contractile proteins.

Authors:  M Sata; H Yamashita; S Sugiura; H Fujita; S Momomura; T Serizawa
Journal:  Pflugers Arch       Date:  1995-01       Impact factor: 3.657

5.  Improved ventricular function by enhancing the Ca++ sensitivity in normal and stunned myocardium of isolated rabbit hearts.

Authors:  B Korbmacher; U Sunderdiek; G Arnold; H D Schulte; J D Schipke
Journal:  Basic Res Cardiol       Date:  1994 Nov-Dec       Impact factor: 17.165

6.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 7.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

8.  Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.

Authors:  S Sasayama; H Asanoi; Y Kihara; S Yokawa; Y Terada; S Yoshida; M Ejiri; I Horikoshi
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

9.  Calcium-supported calpain degradation rates for cardiac myofibrils in diabetes. Sulfhydryl and hydrophobic interactions.

Authors:  A N Belcastro; J S Gilchrist; J A Scrubb; G Arthur
Journal:  Mol Cell Biochem       Date:  1994-06-15       Impact factor: 3.396

10.  Ca2+ sensitizing effects of EMD 53998 after troponin replacement in skinned fibres from porcine atria and ventricles.

Authors:  Z Barth; J D Strauss; S Heyder; J Van Eyk; R J Wiesner; J C Rüegg
Journal:  Pflugers Arch       Date:  1995-06       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.